IVIEW Therapeutics Completes Patient Recruitment for Phase 1/2 Trial of IVW-1001, Exploring New Innovations in Dry Eye Disease and Gene Therapy

Understanding Dry Eye Disease

Dry eye disease is a common condition that occurs when the eyes are unable to produce enough quality tears to maintain proper lubrication, leading to irritation, discomfort, and visual disturbances. Affecting millions globally, the condition often results in chronic symptoms that significantly reduce quality of life. IVIEW Therapeutics aims to address this with the development of IVW-1001, potentially offering a new and effective treatment option.

Advancing Innovation in Dry Eye Disease and Gene Therapy

Industry experts are keeping a close eye on IVIEW Therapeutics’ progress. “The completion of patient enrollment is an important milestone in the development of IVW-1001,” remarked Dr. Houman Hemmati, Chief Medical Advisor at IVIEW Therapeutics. With recruitment finalized, the company moves closer to delivering a novel therapeutic option for dry eye sufferers. The broader ophthalmic community remains optimistic about the results and the potential for improved patient care.

Bo Liang, PhD, CEO and Co-founder of IVIEW Therapeutics, commented on the early completion of recruitment, noting, “This achievement highlights both the dedication of our team and the strong interest from the ophthalmic field. With IVW-1001’s novel TRPM8 activation and its unique delivery method, there is anticipation for how this treatment could make a difference on a global scale. Furthermore, IVIEW continues to explore gene therapy solutions, indicating the company’s broader ambition in revolutionizing ophthalmic treatments.”

About IVIEW Therapeutics Inc.

IVIEW Therapeutics Inc. is a clinical-stage biotech company committed to developing cutting-edge treatments for eye diseases. The company focuses on innovative mechanisms of action and advanced drug delivery platforms to address unmet medical needs. Its portfolio includes a range of therapies targeting conditions such as dry eye disease, myopia, conjunctivitis, glaucoma, presbyopia, and gene therapy development for ophthalmic applications.

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Related Services